## 3 Results
### Nanoparticles for Colorectal Cancer Treatment
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Nanoformulation** & **Chemotherapeutic** & **siRNA** & **Target** & **Targeting Ability** & **In Vitro Results** & **In Vivo Results** & **Ref.** \\ \hline DOTAP (double & & & PEGylated structure & Improved cytotoxicity & A 96.66\% reduction in tumor volume in due to OXA & \\ evaporation technique) & & & (passive) & sensibilization and apoptosis induction (\(\mathcal{W}\)). & compared with free OXA. & [22] \\ \hline Patient endocytic & & & & Decreased cell proliferation and & The combined treatment & \\ primary cell-derived & & & & increased apoptosis & volume by \\ exosomes (transfection) & & & & induction. & 90\% compared to the & \\  & & & & & individual treatments. & \\ \hline  & & & & Cell viability reduction & \\  & & & & and 7.5-fold IC\({}_{50}\) & \\  & & & PEGylated structure & decreased reduction & A 95\% reduction in & \\  & & & & between the synergetic & \\  & & & (passive) & treatment and the & & OXA alone and \\  & & & & one without siRNA in & \\  & & & & resistant lines. & \\ \hline  & & & & Inhibition of M2-like & A 33.33\% tumoral volume & \\  & & & & & polarization of TAMs and & reduction between \\  & & & & (passive) & amplified OXA- & synergetic treatment and & \\  & & & & induced autophagy. & OXA alone. & \\ \hline  & & & & Increased percentage of & A 70.4\% and & \\  & & & & & Internal memory T and & 65.9\% tumoral volume \\  & & & & & central memory T and & reduction with the \\  & & & & & effector memory T cells & synergetic treatment when \\  & & & & by up to 1\% and 3\% in & compared with those \\  & & & & & tumor site CD4+ \({}^{*}\) T cells. & receiving the OXA and \\  & & & & & silIDOI, respectively. & \\ \hline ZIF-8 covered by & & & x-CT & & & A 6-fold reduction in \\  & & & (subunit & \\  & & & SLC/A11) & NS & Improved cytotoxicity in & tumor volume between \\  & & & & the combined therapy. & synergetic treatment and \\ \hline  & & & & IC\({}_{50}\) decreased by & A 4-fold reduction in \\  & & & & 1.8-fold and caspase & tumor volume between \\  & & & & 3/7 increased expression, & \\  & & & & inducing apoptosis. & siRNA alone. \\ \hline  & & & & & Lower COL1A1 & \\ As1411 & & & & expression, decreased & \\ aptamer-conjugated & & & & cell proliferation and & \\  & & & & 5-fold and 3-fold IC\({}_{50}\) & \\  & & & & reduction compared to & \\  & & & & free 5-FU and OXA. & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Nanoparticle-siRNA-drug strategies developed for colorectal cancer treatment. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Nanformulation** & **Chemotherapeutic** & **siRNA** & **Target** & **Targeting Ability** & **In Vitro Results** & **In Vivo Results** & **Ref. ** \\ \hline PEI-PDLLA (two-time hydration method) & Fru & CCAT1 & PEGylated structure (passive) & A 50\% reduction in cell proliferation between the synergic treatment and Fru alone. & A 3-fold reduction and 50\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 31\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 30\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru. & A 31\% inhibition rate of tumor growth in tumor volume between synergic treatment and Fru.